Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study by Verena Wally et al.
Wally et al. Orphanet Journal of Rare Diseases 2013, 8:69
http://www.ojrd.com/content/8/1/69LETTER TO THE EDITOR Open AccessTopical diacerein for epidermolysis bullosa:
a randomized controlled pilot study
Verena Wally1*, Sophie Kitzmueller1, Florian Lagler2, Angelika Moder2, Wolfgang Hitzl3, Martin Wolkersdorfer4,
Peter Hofbauer4, Thomas K Felder5, Michael Dornauer1, Anja Diem1, Nora Eiler1 and Johann W Bauer1Abstract
Blistering in epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is associated with an inflammatory
phenotype, which can be disrupted by diacerein in vitro. In this pilot study we hypothesized, that a topical
formulation of diacerein 1% reduces blistering. Five patients initially applied diacerein underneath both armpits.
Then, each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized
withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks
and remained significantly below the initial level even during withdrawal in four patients. These findings point to a
relevant effect of diacerein and provide important information for a confirmative study.
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EBS-DM is the consequence of dominantly inherited
mutations in either the keratin 5 (K5) or keratin 14 (K14)
gene, which encode proteins constituting the intermedi-
ate filament (IF) network of basal keratinocytes. Muta-
tions lead to an increased mechanical susceptibility of
keratinocytes, manifesting in a collapse of the IF network
[1]. Clinically, patients suffer from blistering of the skin
upon minor trauma, resulting in an impaired quality of
life due to pain and pruritus [2]. In vitro studies on EBS-
DM keratinocytes showed a significant upregulation of
interleukin-1beta (IL-1ß), resulting in the activation of
the c-jun N-terminal-kinase (JNK) stress pathway and
subsequently in the overexpression of K14 and IL-1ß in a
positive feedback loop. When impairing IL-1ß signaling,
using anti-IL-1ß antibody or the small molecule
diacerein, levels of IL-1ß, JNK and K14 decreased and
the IF network was stabilized [3]. Based on this infor-
mation, we launched a double-blinded, randomized,
placebo-controlled pilot study using a 1% diacerein in
the commonly used care cream ultraphil® as intervening
agent, and ultraphil® alone as placebo.* Correspondence: v.wally@salk.at
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reproduction in any medium, provided the orDiacerein, a prodrug of the IL-1 converting enzyme in-
hibitor rhein, is approved for the systemic treatment of
osteoarthritis (Verboril®) [4,5]. It is metabolized in the
liver and cleared by the kidneys. Up to now there are no
data available on topical application.
To test our hypothesis that diacerein is able to reduce
blister formation, we recruited five patients (aged 6 to 48)
with the diagnosis of EBS-DM and a heterozygous amino
acid exchange in K14 protein position 125. An a-priori
sample size computation was done in consideration of a
0.90 power, a 5% significance level and a minimum differ-
ence between blister numbers of 30%. A 25% standard
deviation for the intervention group and 15% for the
placebo group was expected. Computation was done for a
one-sided, paired student t-test. Including a 10% drop-out
rate, the calculation resulted in ten armpits of five patients
to be included (Figure 1A). Randomization was done using
random numbers, with the general requirement that no
patient receives placebo or diacerein on both sides. The
two-phased study started with a six-weeks open phase
(P1), where all patients received 1% diacerein cream to
apply underneath both armpits every evening. Usual care
was continued unchanged. Blister numbers were docu-
mented every second day by the patients and every second
week by a study nurse, who visited the patients at their
homes to avoid any influences from travelling or changes
of habits. Furthermore, patients were requested to taketd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study design comprising an open phase and a controlled-randomized, double-blinded withdrawal. (A) Five patients were
included in the pilot study, all of them harboring a mutation in K14 protein position 125. Initial blister numbers are given. *Note that,
contradictory to an aforegoing patient inquiry, patient DIDM005 did not have any blisters at the first measurement. (B) Representative pictures of
the right armpit of DIDM002 during t1 and t8. (C) The pilot study was a two-phase study with a 6 weeks open phase (P1), followed by a
six-weeks double-blinded, randomized and controlled phase (P2). During P1, patients daily applied 1% diacerein cream underneath both armpits.
During P2, one armpit of each patient was assigned to placebo in a double-blinded and randomized manner. For further data analysis, the study
was divided into eight equidistant time spans (t), each comprising six counts. Patients counted blisters every second day, starting from day 1.
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ware aided quantification of blister areas (Figure 1B). To
optimize the strength of our small pilot trial we added a
second, randomized, placebo-controlled six-weeks phase
(P2), exploiting the fact that placebo and verum could be
used in parallel in the same patient, which virtuallyFigure 2 Results of blister counts show a significant reduction during
both armpits during the open phase P1. During P2, one armpit was assign
(A) During P1, there a significant reduction of blister numbers (given in%) f
left: 22%/CI6-38; mean right: 34%/CI20-48). On both sides, t2 to t8 show a s
* indicating a p-value≤ 0.05). Blister numbers remained low until the end o
confidence intervals, whereby t1 is normalized to 100%. (B) During P2, ther
(* indicates a p-value≤ 0.05).doubled our sample size. Time to loss of efficacy (defined
as halving the effect in P1) was chosen as primary end-
point, because this allows minimizing the time on placebo,
as patients can be de-blinded and switched to verum as
soon as loss of efficacy occurs. For data analysis, we sub-
divided the study period into eight time intervals (t), eachP1. Patients received diacerein (grey graphs) to apply underneath
ed to placebo (black graph) in a double-blinded, randomized manner.
rom time span t1 to time span t2 and from t2 to t3 (t1:100%, t2:mean
ignificant reduction of blisters compared to t1 (upper black line,
f the study period. The mean of blister numbers is given with 95%
e is a significant difference between placebo and diacerein at t7
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did not develop blisters during the study, contradictory to
an aforegoing patient inquiry on times of most strain.
DIDM005 was therefore excluded from the statistical
evaluation. However, it cannot be excluded that the ab-
sence of blisters is due to the treatment. As blister num-
bers are likely to be correlated (two measurements within
the same subject), generalized estimation equations (GEE)
were used. The group (verum/placebo) was the main effect
and time*group was used as interaction effect. The robust
method (Huber/White/sandwich estimator) was used for
estimating the covariance matrix. Pairwise comparisons are
based on the sequential Bonferroni method. The signifi-
cance level was set to 5%. Results showed a statistically
significant reduction of blisters within the first two weeks
of P1 (t1: 100%, t2: mean left: 22%/CI6-38; mean right:
34%/CI20-48), which remained stable until the end of the
study period (Figure 2A). In P2, we could not observe any
loss of efficacy and missed our primary endpoint. Al-
though the relative number of blisters was slightly higher
on the placebo sides, there was only a statistically signifi-
cant difference at t7 (Figure 2B). We believe that carrying-
over of the positive effect from P1 into P2 is the reason
for that observation. Thus, unless missing the primary
statistical objective, the results point to a beneficiary effect
of diacerein.
Clearly, our study is only a pilot and limited by the
low number of patients and the fact that the primary
endpoint was missed. Still, it is a solid basis for planning
an international multi-center study with the aim to
confirm efficacy and safety. The conclusion that will be
regarded in the design of this study comprises:
(a)The chosen dose and treatment regimen can lead to
substantial reduction of blisters within 2 weeks.
(b)This effect seems to be rather stable and can persist
for several weeks after cessation.
(c)Thus, it seems reasonable to include only patients
with a substantial blistering at study entry and study
the reduction of blisters in a randomized controlled
manner.
(d)Furthermore, assessment of blistering should be
done by study staff, because the validity of self-
evaluation showed to be critical, although patients
received a training in blister counting and
foto-documentation.
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